And now to the corporate gerrymander of the year, cancer treatment biotech Novogen. The Board shocked shareholders at the annual meeting in Sydney on November 16 by voting a whopping 160 million shares at the chairman's discretion, up from just 3.1 million at the 2015 AGM.

Remember that two new Novogen directors, Bryce Carmine and Ian Phillips, and a continuing director Steve Coffey, came within a whisker of being unseated that year, with votes for and against their election/re-election split evenly at the close of proxies.